Evidence map›Paper›PMID 25723974›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Evaluating respondent-driven sampling as an implementation tool for universal coverage of antiretroviral studies among men who have sex with men living with HIV.

Stefan D Baral, Sosthenes Ketende, Sheree Schwartz, Ifeanyi Orazulike, Kelechi Ugoh, Sheila A Peel, Julie Ake, William Blattner, Manhattan Charurat

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Stefan D Baral*Key Populations Program, Center for Public Health and Human Rights, Department of Epidemiology, JHSPH, Baltimore, MD; †ICARH, Abuja, Nigeria; ‡Improving Men's Health Initiative, Abuja, Nigeria; §US Military HIV Research Project, Silver Spring, MD; ‖US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD; and ¶Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland, Baltimore, MD.
Sosthenes Ketende
Sheree Schwartz
Ifeanyi Orazulike
Kelechi Ugoh
Sheila A Peel
Julie Ake
William Blattner
Manhattan Charurat
Walter Reed Army Institute of Research · USUniversity of Abuja · NG

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
UM-IHV AITRP in NigeriaD43TW001041 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 1998 to 2015
$9.2M
Building TRUSTR01AI120913 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 2015 to 2019
$3.3M
TRUSTR01MH099001 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 2012 to 2014
$2.9M
FIC NIH HHS D43 TW001041FIC NIH HHS D43TW01041NIAID NIH HHS P30 AI094189NIAID NIH HHS P30AI094189NIAID NIH HHS R01 AI120913NIMH NIH HHS R01 MH099001NIMH NIH HHS R01MH099001-01PHS HHS U2G IPS000651
6 · The paper itself

Abstract

introductionThe TRUST model based on experimental and observational data posits that integration of HIV prevention and universal coverage of antiretroviral treatment at a trusted community venue provides a framework for achieving effective reduction in HIV-related morbidity and mortality among men who have sex with men (MSM) living with HIV, as well as reducing HIV incidence. The analyses presented here evaluate the utility of respondent-driven sampling as an implementation tool for engaging MSM in the TRUST intervention.

methodsThe TRUST integrated prevention and treatment model was established at a trusted community center serving MSM in Abuja, Nigeria. Five seeds have resulted in 3-26 waves of accrual between March 2013 and August 2014, with results presented here characterizing HIV burden and engagement in HIV care for 722 men across study recruitment waves. For analytic purposes, the waves were collapsed into 5 groups: 4 equally spaced (0-4, 5-9, 10-14, and 15-19) and 1 ranging from the 20th to the 26th wave with significance assessed using Pearson χ2 test.

resultsIn earlier waves, MSM were more likely to have reported testing for HIV (82.9% in waves 0-4, 47.7% in waves 20-26; P < 0.01). In addition, biologically confirmed HIV prevalence decreased from an average of 59.1% to 42.9% (P < 0.05) in later waves. In earlier waves, about 80% of participants correctly reported their HIV status as compared with less than 25% in the later waves (P < 0.01). Finally, participants reporting being on ART decreased from 50% to 22.2% in later waves (P < 0.01).

conclusionsImplementation science studies focused on demonstrating impact of universal HIV treatment programs among people living with HIV necessitate different accrual methods than those focused on preventing HIV acquisition. Here, respondent-driven sampling was shown to be an efficient method for reaching marginalized populations of MSM living with HIV in Nigeria, and engaging them in universal HIV treatment services.

Indexed as

Homosexuality, MaleAdolescentAdultAnti-HIV AgentsData CollectionHIV InfectionsHumansMaleNigeriaYoung AdultAnti-HIV Agents

Identifiers

PMID25723974
PMCPMC4481129
OpenAlexW2033708458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.